JP2020520889A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2020520889A5 JP2020520889A5 JP2019550138A JP2019550138A JP2020520889A5 JP 2020520889 A5 JP2020520889 A5 JP 2020520889A5 JP 2019550138 A JP2019550138 A JP 2019550138A JP 2019550138 A JP2019550138 A JP 2019550138A JP 2020520889 A5 JP2020520889 A5 JP 2020520889A5
- Authority
- JP
- Japan
- Prior art keywords
- inhibitor
- pharmaceutical composition
- composition according
- inhibitors
- immunotherapy
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000008194 pharmaceutical composition Substances 0.000 claims 38
- 239000003112 inhibitor Substances 0.000 claims 26
- 229940076838 Immune checkpoint inhibitor Drugs 0.000 claims 19
- 239000012274 immune-checkpoint protein inhibitor Substances 0.000 claims 19
- 238000009169 immunotherapy Methods 0.000 claims 14
- 239000012275 CTLA-4 inhibitor Substances 0.000 claims 10
- 229940045513 CTLA4 antagonist Drugs 0.000 claims 10
- 102000037984 Inhibitory immune checkpoint proteins Human genes 0.000 claims 9
- 108091008026 Inhibitory immune checkpoint proteins Proteins 0.000 claims 9
- 239000012270 PD-1 inhibitor Substances 0.000 claims 9
- 239000012668 PD-1-inhibitor Substances 0.000 claims 9
- 239000000203 mixture Substances 0.000 claims 9
- 229940121655 pd-1 inhibitor Drugs 0.000 claims 9
- 239000012271 PD-L1 inhibitor Substances 0.000 claims 8
- 229940121656 pd-l1 inhibitor Drugs 0.000 claims 8
- 230000002411 adverse Effects 0.000 claims 6
- 206010047115 Vasculitis Diseases 0.000 claims 5
- 102100034458 Hepatitis A virus cellular receptor 2 Human genes 0.000 claims 4
- 101001068133 Homo sapiens Hepatitis A virus cellular receptor 2 Proteins 0.000 claims 4
- 206010061218 Inflammation Diseases 0.000 claims 4
- 208000012659 Joint disease Diseases 0.000 claims 4
- 102000002698 KIR Receptors Human genes 0.000 claims 4
- 239000012272 PD-L2 inhibitor Substances 0.000 claims 4
- 238000002648 combination therapy Methods 0.000 claims 4
- 238000009472 formulation Methods 0.000 claims 4
- 230000004054 inflammatory process Effects 0.000 claims 4
- 229940121654 pd-l2 inhibitor Drugs 0.000 claims 4
- 208000017520 skin disease Diseases 0.000 claims 4
- 229940125563 LAG3 inhibitor Drugs 0.000 claims 3
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 claims 3
- 206010003246 arthritis Diseases 0.000 claims 3
- 206010028417 myasthenia gravis Diseases 0.000 claims 3
- 201000000306 sarcoidosis Diseases 0.000 claims 3
- 206010002556 Ankylosing Spondylitis Diseases 0.000 claims 2
- 208000006545 Chronic Obstructive Pulmonary Disease Diseases 0.000 claims 2
- 206010012438 Dermatitis atopic Diseases 0.000 claims 2
- 101100296720 Dictyostelium discoideum Pde4 gene Proteins 0.000 claims 2
- 206010033645 Pancreatitis Diseases 0.000 claims 2
- 101100082610 Plasmodium falciparum (isolate 3D7) PDEdelta gene Proteins 0.000 claims 2
- 206010035664 Pneumonia Diseases 0.000 claims 2
- 201000004681 Psoriasis Diseases 0.000 claims 2
- 201000001263 Psoriatic Arthritis Diseases 0.000 claims 2
- 208000036824 Psoriatic arthropathy Diseases 0.000 claims 2
- 201000008937 atopic dermatitis Diseases 0.000 claims 2
- 206010009887 colitis Diseases 0.000 claims 2
- 230000000694 effects Effects 0.000 claims 2
- 208000007475 hemolytic anemia Diseases 0.000 claims 2
- 208000006454 hepatitis Diseases 0.000 claims 2
- 231100000283 hepatitis Toxicity 0.000 claims 2
- 238000002649 immunization Methods 0.000 claims 2
- 230000003053 immunization Effects 0.000 claims 2
- 230000002757 inflammatory effect Effects 0.000 claims 2
- 230000002401 inhibitory effect Effects 0.000 claims 2
- 201000008383 nephritis Diseases 0.000 claims 2
- 230000001817 pituitary effect Effects 0.000 claims 2
- 230000002265 prevention Effects 0.000 claims 2
- 230000002829 reductive effect Effects 0.000 claims 2
- 230000008085 renal dysfunction Effects 0.000 claims 2
- 206010039073 rheumatoid arthritis Diseases 0.000 claims 2
- 201000000596 systemic lupus erythematosus Diseases 0.000 claims 2
- 230000000699 topical effect Effects 0.000 claims 2
- 239000012049 topical pharmaceutical composition Substances 0.000 claims 2
- LDVVTQMJQSCDMK-UHFFFAOYSA-N 1,3-dihydroxypropan-2-yl formate Chemical compound OCC(CO)OC=O LDVVTQMJQSCDMK-UHFFFAOYSA-N 0.000 claims 1
- 206010001367 Adrenal insufficiency Diseases 0.000 claims 1
- 239000004322 Butylated hydroxytoluene Substances 0.000 claims 1
- NLZUEZXRPGMBCV-UHFFFAOYSA-N Butylhydroxytoluene Chemical compound CC1=CC(C(C)(C)C)=C(O)C(C(C)(C)C)=C1 NLZUEZXRPGMBCV-UHFFFAOYSA-N 0.000 claims 1
- 206010010741 Conjunctivitis Diseases 0.000 claims 1
- 206010011878 Deafness Diseases 0.000 claims 1
- 208000016192 Demyelinating disease Diseases 0.000 claims 1
- 206010012305 Demyelination Diseases 0.000 claims 1
- 201000004624 Dermatitis Diseases 0.000 claims 1
- 206010012455 Dermatitis exfoliative Diseases 0.000 claims 1
- 208000001380 Diabetic Ketoacidosis Diseases 0.000 claims 1
- SHWNNYZBHZIQQV-UHFFFAOYSA-J EDTA monocalcium diisodium salt Chemical compound [Na+].[Na+].[Ca+2].[O-]C(=O)CN(CC([O-])=O)CCN(CC([O-])=O)CC([O-])=O SHWNNYZBHZIQQV-UHFFFAOYSA-J 0.000 claims 1
- 208000017701 Endocrine disease Diseases 0.000 claims 1
- 206010015150 Erythema Diseases 0.000 claims 1
- 208000010201 Exanthema Diseases 0.000 claims 1
- 208000007465 Giant cell arteritis Diseases 0.000 claims 1
- 208000030836 Hashimoto thyroiditis Diseases 0.000 claims 1
- 101001137987 Homo sapiens Lymphocyte activation gene 3 protein Proteins 0.000 claims 1
- SHBUUTHKGIVMJT-UHFFFAOYSA-N Hydroxystearate Chemical compound CCCCCCCCCCCCCCCCCC(=O)OO SHBUUTHKGIVMJT-UHFFFAOYSA-N 0.000 claims 1
- 206010020850 Hyperthyroidism Diseases 0.000 claims 1
- 208000022559 Inflammatory bowel disease Diseases 0.000 claims 1
- 102000017578 LAG3 Human genes 0.000 claims 1
- 201000009906 Meningitis Diseases 0.000 claims 1
- 206010028372 Muscular weakness Diseases 0.000 claims 1
- 206010066926 Ocular vasculitis Diseases 0.000 claims 1
- 206010033799 Paralysis Diseases 0.000 claims 1
- 206010035742 Pneumonitis Diseases 0.000 claims 1
- 229920002675 Polyoxyl Polymers 0.000 claims 1
- 208000003251 Pruritus Diseases 0.000 claims 1
- 208000025747 Rheumatic disease Diseases 0.000 claims 1
- 206010040914 Skin reaction Diseases 0.000 claims 1
- 206010067584 Type 1 diabetes mellitus Diseases 0.000 claims 1
- 238000010521 absorption reaction Methods 0.000 claims 1
- 208000017515 adrenocortical insufficiency Diseases 0.000 claims 1
- 208000006673 asthma Diseases 0.000 claims 1
- 230000001363 autoimmune Effects 0.000 claims 1
- 201000004339 autoimmune neuropathy Diseases 0.000 claims 1
- 208000010217 blepharitis Diseases 0.000 claims 1
- 210000004204 blood vessel Anatomy 0.000 claims 1
- 210000004556 brain Anatomy 0.000 claims 1
- 229940095259 butylated hydroxytoluene Drugs 0.000 claims 1
- 235000010354 butylated hydroxytoluene Nutrition 0.000 claims 1
- 239000006071 cream Substances 0.000 claims 1
- 201000010099 disease Diseases 0.000 claims 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 1
- 239000003814 drug Substances 0.000 claims 1
- 229940095629 edetate calcium disodium Drugs 0.000 claims 1
- 239000000839 emulsion Substances 0.000 claims 1
- 206010014599 encephalitis Diseases 0.000 claims 1
- 231100000321 erythema Toxicity 0.000 claims 1
- 201000005884 exanthem Diseases 0.000 claims 1
- 208000004526 exfoliative dermatitis Diseases 0.000 claims 1
- 230000001815 facial effect Effects 0.000 claims 1
- 230000010370 hearing loss Effects 0.000 claims 1
- 231100000888 hearing loss Toxicity 0.000 claims 1
- 208000016354 hearing loss disease Diseases 0.000 claims 1
- 229940072106 hydroxystearate Drugs 0.000 claims 1
- 208000003532 hypothyroidism Diseases 0.000 claims 1
- 230000002989 hypothyroidism Effects 0.000 claims 1
- 201000006417 multiple sclerosis Diseases 0.000 claims 1
- 230000036473 myasthenia Effects 0.000 claims 1
- 210000005036 nerve Anatomy 0.000 claims 1
- 201000001119 neuropathy Diseases 0.000 claims 1
- 230000007823 neuropathy Effects 0.000 claims 1
- 239000002674 ointment Substances 0.000 claims 1
- 208000021090 palsy Diseases 0.000 claims 1
- 229940056211 paraffin Drugs 0.000 claims 1
- 239000012188 paraffin wax Substances 0.000 claims 1
- 230000036961 partial effect Effects 0.000 claims 1
- 208000033808 peripheral neuropathy Diseases 0.000 claims 1
- 206010034674 peritonitis Diseases 0.000 claims 1
- 235000019271 petrolatum Nutrition 0.000 claims 1
- 239000000546 pharmaceutical excipient Substances 0.000 claims 1
- 230000006584 pituitary dysfunction Effects 0.000 claims 1
- 238000001959 radiotherapy Methods 0.000 claims 1
- 206010037844 rash Diseases 0.000 claims 1
- 230000000552 rheumatic effect Effects 0.000 claims 1
- 238000009097 single-agent therapy Methods 0.000 claims 1
- 231100000430 skin reaction Toxicity 0.000 claims 1
- 230000035483 skin reaction Effects 0.000 claims 1
- 239000000725 suspension Substances 0.000 claims 1
- 208000011580 syndromic disease Diseases 0.000 claims 1
- 206010043207 temporal arteritis Diseases 0.000 claims 1
- 206010043778 thyroiditis Diseases 0.000 claims 1
- 230000006444 vascular growth Effects 0.000 claims 1
- 239000003871 white petrolatum Substances 0.000 claims 1
Priority Applications (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2023078735A JP2023099217A (ja) | 2017-03-13 | 2023-05-11 | プリナブリン組成物及びその使用 |
| JP2025113816A JP2025138849A (ja) | 2017-03-13 | 2025-07-04 | プリナブリン組成物及びその使用 |
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201762470802P | 2017-03-13 | 2017-03-13 | |
| US62/470,802 | 2017-03-13 | ||
| US201862621528P | 2018-01-24 | 2018-01-24 | |
| US62/621,528 | 2018-01-24 | ||
| PCT/US2018/022064 WO2018169887A1 (en) | 2017-03-13 | 2018-03-12 | Compositions of plinabulin and use thereof |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023078735A Division JP2023099217A (ja) | 2017-03-13 | 2023-05-11 | プリナブリン組成物及びその使用 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2020520889A JP2020520889A (ja) | 2020-07-16 |
| JP2020520889A5 true JP2020520889A5 (enExample) | 2021-04-22 |
| JP7280192B2 JP7280192B2 (ja) | 2023-05-23 |
Family
ID=63522552
Family Applications (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019550138A Active JP7280192B2 (ja) | 2017-03-13 | 2018-03-12 | プリナブリン組成物及びその使用 |
| JP2023078735A Pending JP2023099217A (ja) | 2017-03-13 | 2023-05-11 | プリナブリン組成物及びその使用 |
| JP2025113816A Pending JP2025138849A (ja) | 2017-03-13 | 2025-07-04 | プリナブリン組成物及びその使用 |
Family Applications After (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023078735A Pending JP2023099217A (ja) | 2017-03-13 | 2023-05-11 | プリナブリン組成物及びその使用 |
| JP2025113816A Pending JP2025138849A (ja) | 2017-03-13 | 2025-07-04 | プリナブリン組成物及びその使用 |
Country Status (13)
| Country | Link |
|---|---|
| US (1) | US20200129504A1 (enExample) |
| EP (2) | EP4190326A1 (enExample) |
| JP (3) | JP7280192B2 (enExample) |
| KR (1) | KR102659907B1 (enExample) |
| CN (1) | CN110603037A (enExample) |
| AU (2) | AU2018236168B2 (enExample) |
| BR (1) | BR112019018880A2 (enExample) |
| CA (1) | CA3056077A1 (enExample) |
| DK (1) | DK3595653T3 (enExample) |
| ES (1) | ES2942889T3 (enExample) |
| NZ (1) | NZ757213A (enExample) |
| SG (1) | SG11201908420WA (enExample) |
| WO (1) | WO2018169887A1 (enExample) |
Families Citing this family (20)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR102626155B1 (ko) | 2015-03-06 | 2024-01-17 | 비욘드스프링 파마수티컬스, 인코포레이티드. | Ras 돌연변이와 관련된 암의 치료 방법 |
| JP6904570B2 (ja) | 2015-03-06 | 2021-07-21 | ビヨンドスプリング ファーマシューティカルズ，インコーポレイテッド | 脳腫瘍の治療方法 |
| AU2016291708B2 (en) | 2015-07-13 | 2020-12-24 | Beyondspring Pharmaceuticals, Inc | Plinabulin compositions |
| EP3413885A4 (en) | 2016-02-08 | 2019-09-18 | Beyondspring Pharmaceuticals, Inc. | COMPOSITIONS WITH TUCARESOL OR ITS ANALOG |
| SG11201810872UA (en) | 2016-06-06 | 2019-01-30 | Beyondspring Pharmaceuticals Inc | Composition and method for reducing neutropenia |
| US11633393B2 (en) | 2017-01-06 | 2023-04-25 | Beyondspring Pharmaceuticals, Inc. | Tubulin binding compounds and therapeutic use thereof |
| US11400086B2 (en) | 2017-02-01 | 2022-08-02 | Beyondspring Pharmaceuticals, Inc. | Method of reducing chemotherapy-induced neutropenia |
| GB201713760D0 (en) * | 2017-08-28 | 2017-10-11 | Univ Leuven Kath | Treatment of epilepsy |
| JP7350015B2 (ja) | 2018-01-24 | 2023-09-25 | ビヨンドスプリング ファーマシューティカルズ，インコーポレイテッド | プリナブリンの投与による血小板減少症を軽減するための組成物および方法 |
| WO2019232257A1 (en) * | 2018-06-01 | 2019-12-05 | Beyondspring Pharmaceuticals, Inc. | Composition and method of treating cancer associated with egfr mutation |
| GB201913988D0 (en) | 2019-09-27 | 2019-11-13 | Celleron Therapeutics Ltd | Novel treatment |
| JP2022552011A (ja) * | 2019-10-15 | 2022-12-14 | ビヨンドスプリング ファーマシューティカルズ，インコーポレイテッド | 鉄障害を処置するための方法及び組成物 |
| IL297884A (en) * | 2020-05-04 | 2023-01-01 | Beyondspring Pharmaceuticals Inc | Triple combination therapy to increase cancer cell killing in cancers with low immunogenicity |
| KR102428863B1 (ko) * | 2020-08-11 | 2022-08-03 | 서울대학교병원 | 자가면역 뇌염 발생 가능성 예측을 위한 정보 제공 방법 |
| WO2022133492A1 (en) * | 2020-12-18 | 2022-06-23 | Beyondspring Pharmaceuticals, Inc. | Compositions and methods for generating anti-tumor immune response |
| WO2022216908A1 (en) | 2021-04-09 | 2022-10-13 | Beyondspring Pharmaceuticals, Inc. | Therapeutic compositions and methods for treating tumors |
| CN113456643B (zh) * | 2021-08-11 | 2022-04-01 | 遵义医科大学 | 一种含普那布林的药物组合及其应用 |
| WO2023154755A1 (en) * | 2022-02-10 | 2023-08-17 | Beyondspring Pharmaceuticals, Inc. | Stable plinabulin formulations and methods of their preparation and use |
| CN117860672A (zh) | 2022-10-11 | 2024-04-12 | 大连万春布林医药有限公司 | 一种普那布林胶束组合物及其制备方法 |
| WO2025006507A1 (en) * | 2023-06-27 | 2025-01-02 | Beyondspring Pharmaceuticals, Inc. | Oncology combination therapy and methods of use |
Family Cites Families (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4783443A (en) | 1986-03-03 | 1988-11-08 | The University Of Chicago | Amino acyl cephalosporin derivatives |
| US4919934A (en) | 1989-03-02 | 1990-04-24 | Richardson-Vicks Inc. | Cosmetic sticks |
| US7766013B2 (en) | 2001-06-05 | 2010-08-03 | Alexza Pharmaceuticals, Inc. | Aerosol generating method and device |
| US6737042B2 (en) | 2001-05-24 | 2004-05-18 | Alexza Molecular Delivery Corporation | Delivery of drug esters through an inhalation route |
| US7919497B2 (en) * | 2002-08-02 | 2011-04-05 | Nereus Pharmaceuticals, Inc. | Analogs of dehydrophenylahistins and their therapeutic use |
| US7935704B2 (en) * | 2003-08-01 | 2011-05-03 | Nereus Pharmaceuticals, Inc. | Dehydrophenylahistins and analogs thereof and the synthesis of dehydrophenylahistins and analogs thereof |
| US7064201B2 (en) * | 2002-08-02 | 2006-06-20 | Nereus Pharmaceuticals, Inc. | Dehydrophenylahistins and analogs thereof and the synthesis of dehydrophenylahistins and analogs thereof |
| BRPI0506655A (pt) * | 2004-02-04 | 2007-05-08 | Nereus Pharmaceuticals Inc | dehidrofenilahistinas e seus análogos, e sìntese de dehidrofenilahistinas e seus análogos |
| TW200711649A (en) * | 2005-06-17 | 2007-04-01 | Combinatorx Inc | Combination therapy for the treatment of immunoinflammatory disorders |
| EP1926724A1 (en) * | 2005-09-21 | 2008-06-04 | Nereus Pharmaceuticals, Inc. | Analogs of dehydrophenylahistins and their therapeutic use |
| WO2012035436A1 (en) * | 2010-09-15 | 2012-03-22 | Tokyo University Of Pharmacy And Life Sciences | Plinabulin prodrug analogs and therapeutic uses thereof |
| JP6311097B2 (ja) * | 2013-07-31 | 2018-04-18 | 学校法人東京薬科大学 | 微小管脱重合剤 |
| CA2926771C (en) * | 2013-10-11 | 2022-07-05 | Beyondspring Pharmaceuticals, Inc. | Cancer treatment with combination of plinabulin and taxane |
| US20180028531A1 (en) | 2015-02-12 | 2018-02-01 | BeyondSpring Phamaceuticals, Inc. | Use of plinabulin in combination with immune checkpoint inhibitors |
| EP3413885A4 (en) * | 2016-02-08 | 2019-09-18 | Beyondspring Pharmaceuticals, Inc. | COMPOSITIONS WITH TUCARESOL OR ITS ANALOG |
-
2018
- 2018-03-12 CA CA3056077A patent/CA3056077A1/en active Pending
- 2018-03-12 SG SG11201908420W patent/SG11201908420WA/en unknown
- 2018-03-12 JP JP2019550138A patent/JP7280192B2/ja active Active
- 2018-03-12 BR BR112019018880A patent/BR112019018880A2/pt active Search and Examination
- 2018-03-12 US US16/493,271 patent/US20200129504A1/en not_active Abandoned
- 2018-03-12 AU AU2018236168A patent/AU2018236168B2/en active Active
- 2018-03-12 EP EP23153650.9A patent/EP4190326A1/en not_active Withdrawn
- 2018-03-12 EP EP18768238.0A patent/EP3595653B1/en active Active
- 2018-03-12 NZ NZ757213A patent/NZ757213A/en unknown
- 2018-03-12 ES ES18768238T patent/ES2942889T3/es active Active
- 2018-03-12 DK DK18768238.0T patent/DK3595653T3/da active
- 2018-03-12 WO PCT/US2018/022064 patent/WO2018169887A1/en not_active Ceased
- 2018-03-12 CN CN201880029191.0A patent/CN110603037A/zh active Pending
- 2018-03-12 KR KR1020197029387A patent/KR102659907B1/ko active Active
-
2023
- 2023-05-11 JP JP2023078735A patent/JP2023099217A/ja active Pending
-
2024
- 2024-02-06 AU AU2024200709A patent/AU2024200709A1/en not_active Abandoned
-
2025
- 2025-07-04 JP JP2025113816A patent/JP2025138849A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2020520889A5 (enExample) | ||
| Tynjälä et al. | Adalimumab in juvenile idiopathic arthritis-associated chronic anterior uveitis | |
| Vallabhaneni et al. | Fungal infections and new biologic therapies | |
| Venning et al. | British Association of Dermatologists’ guidelines for the management of bullous pemphigoid 2012 | |
| JP5456658B2 (ja) | 抗体製剤 | |
| Kanwar et al. | Pemphigus in India | |
| Harris et al. | Update on the treatment of juvenile idiopathic arthritis | |
| CN113329754A (zh) | 用于施用皮质类固醇的方法 | |
| US11976113B2 (en) | Biopharmaceutical compositions comprising nucleic acids encoding IL-5 binding proteins | |
| TW202146048A (zh) | 含有il-31拮抗劑作為有效成分之異位性皮膚炎的預防用及/或治療用醫藥組合物 | |
| IL292706A (en) | Type i interferon inhibition in systemic lupus erythematosus | |
| Bou et al. | Treatment of uveitis associated with juvenile idiopathic arthritis | |
| CN120501855A (zh) | 给予抗cd38抗体以治疗多发性骨髓瘤的方法 | |
| Hoy | Canakinumab: a review of its use in the management of systemic juvenile idiopathic arthritis | |
| JP7286665B2 (ja) | ＩｇＥ介在アレルギー性疾患の治療 | |
| Cansu et al. | Is it required to routinely check fibrinogen level in patients with rheumatic diseases on tocilizumab? Case-based review | |
| Kuroyanagi et al. | Effectiveness and nephrotoxicity of a 2-year medium dose of cyclosporine in pediatric patients with steroid-dependent nephrotic syndrome: determination of the need for follow-up kidney biopsy | |
| US20230158033A1 (en) | Method of Treating Pemphigus by Administering (R)-2-[3-[4-Amino-3-(2-Fluoro-4-Phenoxy-Phenyl)Pyrazolo[3,4-D]Pyrimidin-1-YL]Piperidine-1-Carbonyl]-4-Methyl-4-[4-(Oxetan-3-YL)Piperazin-1-YL]Pent-2-Enenitrile | |
| Van Helmond et al. | Real-world Effectiveness and Safety of Janus Kinase Inhibitors in Alopecia Areata: A Retrospective Cohort Study of 72 Patients | |
| US20250042985A1 (en) | Interleukin 5 binding protein dosage regimen for use in treating polyangiitis, hypereosinophilic syndrome, chronic rhinosinusitis with nasal polyps (crswnp), or chronic rhinosinusitis without nasal polyps (crssnp) | |
| Parisian et al. | Management of steroid-dependent and steroid-refractory ulcerative colitis | |
| EP4644416A2 (en) | Interleukin 5 binding protein dosage regimen | |
| Mastrobuoni et al. | Two-dose daclizumab, tacrolimus, mycophenolate mofetil, and steroid-free regimen in de novo cardiac transplant recipients: early experience | |
| Kaplan et al. | Corticotrophins, corticosteroids, and prostaglandins | |
| CA3252743A1 (en) | METHODS AND COMPOSITIONS FOR THE TREATMENT OF DISEASES ASSOCIATED WITH IGG4 |